Safety of zaleplon in the treatment of insomnia

Annals of Pharmacotherapy

Volumn 36, Issue 5, 2002, Pages 852-859

  Israel, Andrew Glenn ^a   Kramer, Jeffrey A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical Services   (United States)

Author keywords

Benzodiazepines; Drug safety; Hypnotic agents; Insomnia; Zaleplon

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; ALDEHYDE OXIDASE; BENZODIAZEPINE; CYTOCHROME P450 3A4; FLURAZEPAM; HYPNOTIC AGENT; IBUPROFEN; IMIPRAMINE; PAROXETINE; PLACEBO; THIORIDAZINE; TRIAZOLAM; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ABDOMINAL PAIN; AMNESIA; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; EVALUATION; HEADACHE; HUMAN; INSOMNIA; MEDLINE; META ANALYSIS; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REBOUND; REVIEW; RHINITIS; SEDATION; SOMNOLENCE; VERTIGO; WITHDRAWAL SYNDROME;

ACETAMIDES; BENZODIAZEPINES; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; PSYCHOMOTOR DISORDERS; PYRIMIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0036098399     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A086     Document Type: Review

References (69)

1. Economic effects of insomnia
2. Issues in the diagnosis and treatment of insomnia
3. Diagnosis and management of insomnia
4. Prevalence of sleep disturbance in a primarily urban Florida county
5. Epidemiology of sleep disorders
6. Sleep complaints among elderly persons: An epidemiologic study of three communities
7. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I
8. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II
9. Sleep disorders
10. Issues in the use of benzodiazepine therapy
11. Geriatrics: Sleep disorders and aging
12. Hypnotics: Clinical pharmacology and therapeutics
13. Trazodone for antidepressant-associated insomnia
14. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients
15. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia
16. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
17. Treatment of insomnia in hospitalized patients
18. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem
19. Areceptors different from zolpidem, zopiclone and benzodiazepines
20. Efficacy and safety of zaleplon at peak plasmalevels
21. Zaleplon
22. Zaleplon vs. zolpidem: Differences in next-day residual sedation after middle-of-the-night administration
23. Pharmacology of benzodiazepine hypnotics
24. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
25. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia
26. Tolerance and rebound insomnia with rapidly eliminated hypnotics: A meta-analysis of sleep laboratory studies
27. Hypnotics in the elderly
28. The use of sedative/hypnotic medication and its correlation with falling down in the hospital
29. Psychotropic drug use and the risk of hip fracture
30. Association of road-traffic accidents with benzodiazepine use
31. Sedative-hypnotics and human performance
32. Next-day memory impairment with triazolam use
33. ABC of sleep disorders. Withdrawal from hypnotic drugs
34. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers
35. Prescribing information. Sonata (zaleplon) capsules
36. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo
37. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam
38. Pharmacology of CL 284,846, a non-benzodiazepine sedative with reduced amnestic liability
39. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia
40. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
41. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic
42. A placebocontrolled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic
43. Perceptual disturbances with zaleplon
44. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance
45. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia
46. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
47. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia
48. Roth T Daytime function and benzodiazepine effects in insomniacs compared to normals
49. Effects of daytime administration of zolpidem versus triazolam on memory
50. Zalepton 5 mg and 10 mg for the treatment of elderly primary insomniacs
51. Benzodiazepine dependence
52. A 28-night evaluation of the efficacy, next-day effects, and withdrawal potential of zaleplon and zolpidem in outpatients with primary insomnia
53. The safety of long-term treatment of insomnia with zaleplon
54. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects
55. Zaleplon provides safe long-term treatment of insomnia in the elderly
56. Zaleplon and triazolam in humans: Acute behavioral effects and abuse potential
57. Overview of drug-interaction studies with zaleplon
58. Absence of an interaction between ibuprofen and zaleplon
59. Effects of zaleplon or triazolam with or without ethanol on human performance
60. Psychomotor effects of zaleplon and thioridazine coadministration
61. The lack of drug interaction between zaleplon (Sonata) and venlafaxine ER (Effexor XR)
62. Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics
63. Effects on the pharmacokinetics of zaleplon resulting from inhibition of its primary (aldehyde oxidase) and secondary (CYP3A4) metabolic pathways
64. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats
65. Inhibition of human and guinea-pig liver aldehyde oxidases in-vitro
66. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms
67. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin